PRCT has 36-month beta value of 0.98. Analysts have mixed views on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for PRCT is 48.40M, and currently, short sellers hold a 9.26% ratio of that float. The average trading volume of PRCT on June 28, 2024 was 601.72K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
PRCT) stock’s latest price update
Procept BioRobotics Corp (NASDAQ: PRCT) has experienced a rise in its stock price by 1.92 compared to its previous closing price of 59.73. However, the company has seen a gain of 1.60% in its stock price over the last five trading days. investorplace.com reported 2024-06-27 that Right now, growth investors are focused primarily on opportunities in the semiconductors and artificial intelligence stocks space. That’s understandable, given how fast technology is advancing in those areas right now.
PRCT’s Market Performance
PRCT’s stock has risen by 1.60% in the past week, with a monthly drop of -5.03% and a quarterly rise of 23.19%. The volatility ratio for the week is 3.14% while the volatility levels for the last 30 days are 3.38% for Procept BioRobotics Corp The simple moving average for the past 20 days is -4.55% for PRCT’s stock, with a 32.41% simple moving average for the past 200 days.
Analysts’ Opinion of PRCT
Many brokerage firms have already submitted their reports for PRCT stocks, with Piper Sandler repeating the rating for PRCT by listing it as a “Overweight.” The predicted price for PRCT in the upcoming period, according to Piper Sandler is $42 based on the research report published on August 11, 2023 of the previous year 2023.
PRCT Trading at -1.59% from the 50-Day Moving Average
After a stumble in the market that brought PRCT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -20.94% of loss for the given period.
Volatility was left at 3.38%, however, over the last 30 days, the volatility rate increased by 3.14%, as shares sank -5.03% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +17.76% upper at present.
During the last 5 trading sessions, PRCT rose by +1.79%, which changed the moving average for the period of 200-days by +79.49% in comparison to the 20-day moving average, which settled at $63.62. In addition, Procept BioRobotics Corp saw 45.26% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at PRCT starting from Nouri Alaleh, who sale 10,000 shares at the price of $62.18 back on Jun 17 ’24. After this action, Nouri Alaleh now owns 52,472 shares of Procept BioRobotics Corp, valued at $621,764 using the latest closing price.
Shiblaq Hisham, the EVP, Chief Comm. Officer of Procept BioRobotics Corp, sale 26,046 shares at $68.24 during a trade that took place back on Jun 10 ’24, which means that Shiblaq Hisham is holding 55,860 shares at $1,777,499 based on the most recent closing price.
Stock Fundamentals for PRCT
Current profitability levels for the company are sitting at:
- -0.69 for the present operating margin
- 0.53 for the gross margin
The net margin for Procept BioRobotics Corp stands at -0.66. The total capital return value is set at -0.32. Equity return is now at value -47.29, with -30.98 for asset returns.
Based on Procept BioRobotics Corp (PRCT), the company’s capital structure generated 0.17 points at debt to capital in total, while cash flow to debt ratio is standing at -1.97. The debt to equity ratio resting at 0.2. The interest coverage ratio of the stock is -51.25.
Currently, EBITDA for the company is -105.36 million with net debt to EBITDA at 1.38. When we switch over and look at the enterprise to sales, we see a ratio of 19.09. The receivables turnover for the company is 2.79for trailing twelve months and the total asset turnover is 0.41. The liquidity ratio also appears to be rather interesting for investors as it stands at 8.52.
Conclusion
To put it simply, Procept BioRobotics Corp (PRCT) has had a better performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
